Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],1.96,213259,DB00418,Secobarbital
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],2.58,213260,DB00418,Secobarbital
,7110754,rate of absorption,"The rate of absorption of secobarbital, as measured by the time to reach peak serum concentration, was much more rapid from the solution than the suppository (0.92 +/- 0.47 hr vs 4.60 +/ 2.30 hr).",Rectal absorption and disposition of secobarbital in epileptic children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),h,0.92,217840,DB00418,Secobarbital
,7110754,rate of absorption,"The rate of absorption of secobarbital, as measured by the time to reach peak serum concentration, was much more rapid from the solution than the suppository (0.92 +/- 0.47 hr vs 4.60 +/ 2.30 hr).",Rectal absorption and disposition of secobarbital in epileptic children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),h,4.60,217841,DB00418,Secobarbital
,7110754,time to reach peak serum concentration,"The rate of absorption of secobarbital, as measured by the time to reach peak serum concentration, was much more rapid from the solution than the suppository (0.92 +/- 0.47 hr vs 4.60 +/ 2.30 hr).",Rectal absorption and disposition of secobarbital in epileptic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),h,0.92,217842,DB00418,Secobarbital
,7110754,time to reach peak serum concentration,"The rate of absorption of secobarbital, as measured by the time to reach peak serum concentration, was much more rapid from the solution than the suppository (0.92 +/- 0.47 hr vs 4.60 +/ 2.30 hr).",Rectal absorption and disposition of secobarbital in epileptic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),h,4.60,217843,DB00418,Secobarbital
,7110754,peak serum concentration,The peak serum concentration of secobarbital in the solution group was consistently higher than in the suppository group (2.26 +/- 0.37 micrograms/ml vs 1.35 +/- 0.24 microgram/ml).,Rectal absorption and disposition of secobarbital in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),[μg] / [ml],2.26,217844,DB00418,Secobarbital
,7110754,peak serum concentration,The peak serum concentration of secobarbital in the solution group was consistently higher than in the suppository group (2.26 +/- 0.37 micrograms/ml vs 1.35 +/- 0.24 microgram/ml).,Rectal absorption and disposition of secobarbital in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),[μg] / [ml],1.35,217845,DB00418,Secobarbital
exceeded,7110754,peak serum concentrations,"None of the individual peak serum concentrations exceeded 3 micrograms/ml, which is well below the previously reported minimum toxic concentration of secobarbital (ie, 6 microgram/ml).",Rectal absorption and disposition of secobarbital in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),[μg] / [ml],3,217846,DB00418,Secobarbital
,7110754,minimum toxic concentration,"None of the individual peak serum concentrations exceeded 3 micrograms/ml, which is well below the previously reported minimum toxic concentration of secobarbital (ie, 6 microgram/ml).",Rectal absorption and disposition of secobarbital in epileptic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),[μg] / [ml],6,217847,DB00418,Secobarbital
,7110754,elimination half-life,"The elimination half-life of secobarbital varied over a wide range, from 2.7 to 13.5 hr, and is, on the average, shorter than estimates previously reported for adult volunteers or poly-drug abusers.",Rectal absorption and disposition of secobarbital in epileptic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110754/),h,2.7 to 13.5,217848,DB00418,Secobarbital
,6845397,clearance,"Prior to barbiturate treatment, theophylline clearance was 4.78 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.78,221737,DB00418,Secobarbital
,6845397,peak value,"After 29 days of barbiturate administration, theophylline clearance attained a peak value of 16.1 ml/kg/min, an increase of 337% from the prebarbiturate rate.",Effect of secobarbital on theophylline clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],16.1,221738,DB00418,Secobarbital
,6845397,clearance,"After secobarbital was discontinued, theophylline clearance returned to 4.53 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.53,221739,DB00418,Secobarbital
,7924124,kd,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),1/[h],0.054,254945,DB00418,Secobarbital
,7924124,"Cu50,S","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],0.0026,254946,DB00418,Secobarbital
,7924124,"Cu50,R","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],3.45,254947,DB00418,Secobarbital
,7924124,gamma,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),,0.90,254948,DB00418,Secobarbital
,7924124,td,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),h,8.2,254949,DB00418,Secobarbital
